If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

PSE - Awards Finalist

5 Jun 2007 11:03

Imperial Innovations Group plc05 June 2007 5 June 2007 Imperial Innovations Group plc ("Imperial Innovations") PSE Finalist for MacRobert Award Imperial Innovations Group plc (AIM: IVO), the technology commercialisation andinvestment company, announces that an Imperial Innovations spin-out company,Process Systems Enterprise (PSE), was today revealed to be one of the fourfinalists for the Royal Academy of Engineering's MacRobert Award. The award, theUK's most prestigious for engineering, recognises the successful development ofinnovative ideas in engineering. The winning company is honoured with a goldmedal and the winning team members receive a prize of £50,000. Process Systems Enterprise was selected for its innovative gPROMS(R) advancedprocess modelling software. gPROMS helps process industry companies to maximiseproduct quality, minimise production cost and control environmental impactthrough the use of high-accuracy predictive mathematical models of theirprocesses. It also enables them to innovate much faster, design more efficientprocesses, manage risk closely and integrate R&D and engineering disciplines. gPROMS has successfully entered the worldwide market, with 75% of PSE's revenuescoming from exports. The company's client base includes more than 60 of theworld's leading process industry companies, about 75% of which are Fortune 500organisations. gPROMS is also being used for teaching and research by more than200 universities worldwide. The company was formed in 1997 by Imperial Innovations and is based ontechnology arising from the research of Professor Costas Pantelides andcolleagues from the Centre for Process Systems Engineering at Imperial CollegeLondon. Prof. Costas Pantelides, MD of PSE, says "The process industry is going througha period of significant opportunities and challenges: unprecedented demand forproducts, increasing customer expectations of product performance, decreasingavailability of primary raw materials, and global concerns relating to energyconsumption, safety and environmental impact. We bring the means to make sounddecisions while minimising the risk inherent in innovation". Susan Searle, CEO of Imperial Innovations said, "Imperial Innovations isdelighted that PSE is being considered for the MacRobert awards. We recognisethe tremendous progress and future potential of PSE, and are working with thecompany closely to develop new geographical markets and sectors for its growth.In particular, we see that PSE has major potential in the environment sectorwhere companies are designing new product manufacturing methods with lowercarbon footprints and large metropolitan areas are developing moreenvironmentally sustainable urban systems. We are helping PSE find new channelpartners to accelerate its growth and realise its full potential." -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsHarriet Totty / Eleanor Williamson +44 (0)20 7153 1539 JP Morgan Cazenove +44 (0)20 7588 2828Steve Baldwin Notes to Editors About Imperial InnovationsImperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £26 million. The company's integrated approach encompassesthe identification of ideas, protection of intellectual property, developmentand licensing of technology and formation, incubation and investment intechnology businesses. A wide range of technologies are commercialised withinthe areas of healthcare, energy, environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in70 technology businesses and has completed 116 commercial agreements. ImperialInnovations also commercialises technologies originating from outside ImperialCollege through incubation contracts with the Carbon Trust and WRAP and hasrelationships with a number of multinational corporations including BAE Systems. Imperial Innovations has invested in a range of spin-out companies, includingThe Acrobot Company Limited, BioCeramic Therapeutics Limited, Cardiak Limited,Circassia Holdings Limited, deltaDOT Limited, Equinox Pharma Limited, FutureWaves PTE Limited, HeliSwirl Technologies Limited, InforSense Limited, IXICOLimited, Lontra Limited, Midaz Lasers Limited, NanoBioDesign Limited, NexeonLimited, NovaThera Limited, Thiakis Limited and Veryan Medical Limited. Imperial Innovations currently holds shares in four technology businesses nowlisted on AIM including the fuel cell company, Ceres Power plc. www.imperialinnovations.co.uk About Process Systems Enterprise Ltd PSE (www.psenterprise.com) is one of the world's foremost providers of AdvancedProcess Modelling software and Model-Based Innovation services to the processmanufacturing industries. These apply high-accuracy mathematical models ofprocess equipment and phenomena to provide high-quality information for decisionsupport in process innovation, design and operation. Use of PSE's technology and services results in faster innovation, improveddesigns of processes and products, enhancement of existing operations and moreeffective R&D and experimental programmes. Results are achieved with relativelylow investment compared to alternative approaches - where these exist - withrapid return on investment and transfer of modelling know-how to industry. PSE's global customer base of process manufacturing companies and theirtechnology suppliers is served by offices in the UK, USA, Germany and Japan, andagencies in China, India and Korea. About gPROMS gPROMS(R) is the world's leading Advanced Process Modelling (APM) environment.It is used to provide high-quality information for decision support ininnovation, design and operation across all sectors of the process industries,with particular focus on modelling of complex operations such as reaction,crystallisation and polymerisation. Companies apply gPROMS to reduce time-to-market for new processes or products,improve designs, enhance production, reduce capital and operating expenditureand comply more effectively with safety, health and environmental requirements. gPROMS is applied across the 'process lifecycle', from laboratoryexperimentation, through process and detailed design, to online operation, andis central to the emerging technology of Model-Based Innovation. PSE iscommitted to maintaining gPROMS at the leading edge of modelling technology. http://www.psenterprise.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Dec 20123:02 pmRNSResult of AGM
16th Nov 20127:00 amRNSVeryan CE Mark approval for BioMimics 3D Stent
5th Nov 20127:00 amRNSPortfolio companies receive government funding
19th Oct 201210:00 amRNSGrant of share options
5th Oct 20127:00 amRNSFull year results
4th Oct 20127:00 amRNSCircassia initiates phase III trial
26th Sep 20127:00 amRNSPsiOxus commences clinical trial
20th Sep 201212:39 pmRNSNotice of Results
13th Sep 20123:25 pmRNSCircassia appoints Dr Brett Haumann as CMO
12th Sep 201211:35 amRNSAward Win
6th Sep 20127:00 amRNSInvestment in Cambridge technology company
1st Aug 20123:58 pmRNSDirector Dealings
23rd Jul 20127:00 amRNSInvestment in portfolio company
11th Jul 20122:50 pmRNSVeryan Medical appoints new COO and NEDs
9th Jul 20127:00 amRNS£22m funding round for PsiOxus Therapeutics
5th Jul 20125:20 pmRNSGrant of share options
27th Jun 20128:12 amRNSAbingdon Health acquires controlling stake
18th Jun 20127:00 amRNSInvestment in Oxford healthcare company
12th Jun 20127:00 amRNSInvestment in Cambridge technology company
31st May 20129:36 amRNSDirector/PDMR Shareholding
29th May 201210:05 amRNSPolytherics expands relationship with Pro Bono Bio
24th May 20127:00 amRNSDirector Dealings
1st May 20123:04 pmRNSDirector Dealings
23rd Apr 20127:00 amRNSHalf year results
26th Mar 20123:51 pmRNSNotice of Results
26th Mar 20127:00 amRNSInvestment in portfolio company
21st Mar 20127:00 amRNSDirectorate Change
8th Mar 20127:00 amRNSCircassia Phase II Clinical Trial Success
13th Feb 20127:00 amRNSInvestment in portfolio company
14th Dec 20115:27 pmRNSResult of AGM
6th Dec 20117:00 amRNSInvestment in new start-up
5th Oct 20117:00 amRNSFinal Results
27th Sep 20118:56 amRNSNotice of Results
7th Sep 20117:00 amRNSFurther investment in portfolio company
25th Aug 20117:00 amRNSInvestment in Cambridge company
22nd Aug 20117:00 amRNSInvestment in new company
3rd Aug 20117:00 amRNSInvestment in portfolio company
20th Jul 20117:00 amRNSInvestment in Stanmore
22nd Jun 20119:35 amRNSPortfolio company joint venture
19th Apr 20117:00 amRNSCircassia raises £60m
19th Apr 20117:00 amRNSHalf Yearly Report
30th Mar 201112:41 pmRNSNotice of Results
7th Feb 20116:00 pmRNSNotification of major interest in shares
3rd Feb 20118:16 amRNSDirectors' Dealings
27th Jan 20112:56 pmRNSNotification of major interest in shares
27th Jan 20112:51 pmRNSNotification of major interest in shares
26th Jan 20116:01 pmRNSNotification of major interest in shares
25th Jan 20116:03 pmRNSDirectors' Dealings
25th Jan 20115:40 pmRNSResults of Rump placing
24th Jan 20114:11 pmRNSVoting rights & share capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.